ASH 2022 | Risk factors for success or failure of CD19-directed CAR-T therapy in children with B-ALL
Regina Myers, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, outlines risk factors for success or failure of CD19-directed CAR-T therapy in children with B-cell acute lymphoblastic leukemia (B-ALL), highlighting how they may be used to guide treatment and monitoring. Patients with fewer lines of therapy (LOT) or with low disease burden are considered at a lower risk to relapse after CAR-T, whereas higher-risk patients who have a high disease burden and who have received more LOT should be closely monitored, and additional therapy should be considered. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
